News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: Lirumlarum1

ImmunityBio ASCO results show promise for therapies in bladder and pancreatic cancers Jun. 06, 2022 10:39 AM ETImmunityBio, Inc. (IBRX)By: Jonathan Block, SA News Editor https://seekingalpha.com/news/3845957-immunitybio-asco-results-show-promise-for-therapies-in-bladder-and-pancreatic-cancers

ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting JUNE 6, 2022 Data from trials underscore ImmunityBio’s vision of activating NK cells and T cells to advance care in difficult-to-treat cancers Bladder Cancer: 71% of BCG-unresponsive NMIBC patients who had failed on previous therapies showed a complete response with a median duration of 26.6 months; cystectomy avoidance rate of 91% and 100% bladder cancer overall survival at 24 months with 0% immune-related serious adverse events (SAE) Advanced Metastatic Pancreatic Cancer: Nant Vaccine more than doubled median overall survival for patients versus historical overall survival with median overall survival in patients with third- to sixth-line pancreatic cancer at 6.2 months and treatment-related SAEs uncommon (6%) ImmunityBio is exhibiting at booth number 26135 https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-quilt-trial-results-bcg-unresponsive?field_nir_news_date_value[min]=

https://www.pharmaceutical-technology.com/comment/immunitybio-first-marketed-drug/

ImmunityBio, Inc. @ImmunityBio 1 Std. At #ASCO22, Dr. Tara Seery presents: Phase 2 clinical trial of DAMP inducers combined with IL15 superagonist, N-803, and anti–PD-L1 NK cell therapy more than doubles historical overall survival in patients with 3rd-6th line advanced pancreatic cancer. https://bit.ly/3wYcNsk

ImmunityBio: Ready To Shift Gears After Long-Awaited BLA Submission https://seekingalpha.com/article/4516099-immunitybio-ready-to-shift-gears-after-long-awaited-bla-submission

ImmunityBio, Inc. @ImmunityBio 5 Min. Most cancer treatment plans weaken the immune system. At ImmunityBio, we work to create targeted immunotherapies designed to strengthen the immune system and outsmart the disease. This is why #CancerResearch is so imperative. https://immunitybio.com #NationalCancerResearchMonth

ImmunityBio, Inc. @ImmunityBio #ICYMI: ImmunityBio submitted a Biologics License Application to the US #FDA for N-803 for intravesical administration plus #BCG for patients with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (#NMIBC CIS).

Dr. Pat Soon-Shiong @DrPatSoonShiong 8 Std. Importance of that paper : “vaccines that do not provide sterilizing immunity (and therefore continue to permit transmission) will lead to a buildup of large standing populations of virus, greatly increasing the risk of immune escape.”

Dr. Pat Soon-Shiong @DrPatSoonShiong Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein

DUNKIRk: No easy path ahead for ImmunityBio ImmunityBio’s entrance into the northern Chautauqua County economy seemed promising earlier this year. Founded by billionaire Dr. Patrick Soon-Shiong, the company had high hopes after purchasing the former Athenex manufacturing facility. Recent numbers, however, are not as optimistic. As reported over this weekend, the early May filing with the SEC shows ImmunityBio losing $102,998,000 in the first three months of 2022 compared with a loss of $80,481,000 over the same time period in 2021. Overall, the company has lost $2.1 billion since it was founded, with losses coming from the costs of ongoing clinical trials and operations and research and development programs. “We have no clinical products approved for commercial sale and have not generated any revenue from therapeutic and vaccine product candidates that are under development,” the company reported in the filing. Former tenant of the site off Route 5 in Athenex, we must note, is suffering as well as its stock price continued to tumble. That being said, ImmunityBio has some major hurdles ahead of it. Some of their treatments being studied in clinical trials involve cancers and COVID-19 vaccine. As the world of health care continues to evolve, there’s been a fair share of uncertainty. As a new partner to Dunkirk, ImmunityBio is clearly in that mix. https://www.observertoday.com/opinion/the-observers-view/2022/05/dunkirk-no-easy-path-ahead-for-immunitybio/

ImmunityBio, Inc. @ImmunityBio 3 Std. See these ImmunityBio papers for details on our COVID-19 vaccine research: https://www.biorxiv.org/content/10.1101/2021.11.29.470440v2

ImmunityBio, Inc. @ImmunityBio 3 Std. Timely paper by Vall d’Hebron researchers, et al., suggests mRNA vaccines elicit only very modest memory T cell protection against SARS-CoV-2 in the lung. This has been our hypothesis since the onset of the pandemic. @vallhebron

ImmunityBio, Inc. @ImmunityBio One more week - our @ASCO booth info: https://info.immunitybio.com/asco2022 #ASCO2022 #oncology #biotech #clinicaltrials #NMIBC #pancreaticcancer $IBRX

ImmunityBio, Inc. @ImmunityBio 26. Mai #DYK #NMIBC CIS affects tens of thousands of people every year. This week ImmunityBio submitted a Biologics License Application (BLA) for N-803 for intravesical administration plus #BCG for patients with BCG-unresponsive NMIBC CIS. From @YahooFinance

We have entered into an open market sale agreement (the sale agreement) with Jefferies LLC (Jefferies) relating to shares of our common stock, $0.0001 par value per share, offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sale agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $500,000,000 from time to time through Jefferies, acting as our sales agent, of which $169,204,018 have been previously sold, leaving $330,795,982 of shares in this offering. https://newsfilter.io/a/0c95c054316188c6e59d83b6199922b7

Dr. Pat Soon-Shiong @DrPatSoonShiong FDA Will Assess Data On T-Cell Levels Produced By COVID-19 Vaccines FDA has started gathering more data on T-cell levels in people who have been vaccinated against COVID-19. So glad. Finally getting there. The only way to stop transmission and attack Long COVID @covid #tcell 3:54 vorm. · 25. Mai 2022· https://mobile.twitter.com/drpatsoonshiong/status/1529279776795643905